Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer
Your Article Summary
See Latest ArticlesEGFR inhibitors as first-line therapy in advanced non-small cell lung cancer
Journal of Thoracic Oncology, 03/06/08
Fong T et al. - Tyrosine kinase inhibitors (TKIs) of the epidermal growth factor receptor (EGFR), erlotinib and gefitinib, are active agents in the treatment of advanced non-small cell lung cancer (NSCLC). Patients with advanced NSCLC who are life long never-smokers, have EGFR TK mutations, and those with bronchioloalveolar cell carcinoma histology seem to have promising efficacy with first-line therapy with EGFR TKIs. This review summarizes the results of clinical trials on erlotinib or gefitinib, and describes the ongoing studies with these agents in NSCLC.
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
First-line cisplatin with docetaxel or vinorelbine in patients with advanced non-small-cell lung cancer: A quality of life directed phase II randomized trial of Gruppo Oncologico Italia Meridionale
Lung Cancer, 11/20/09
High Level of Cross-Resistance between Kanamycin, Amikacin, and Capreomycin among Mycobacterium tuberculosis Isolates from Georgia and a Close Relation with Mutations in the rrs Gene
Antimicrobial Agents and Chemotherapy, 11/20/09
Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC Clinical Trials Group BR24 Study
Journal of Clinical Oncology, 11/19/09
Today in Lung/Thoracic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Relapse in resected lung cancer revisited: does intensified follow up really matter? A prospective study
World Journal of Surgical Oncology, 11/20/09
First-line cisplatin with docetaxel or vinorelbine in patients with advanced non-small-cell lung cancer: A quality of life directed phase II randomized trial of Gruppo Oncologico Italia Meridionale
Lung Cancer, 11/20/09
Tumor necrosis factor inhibitors and lung disease: A paradox of efficacy and risk
Seminars in Arthritis and Rheumatism, 11/20/09
Sponsor
Article Search
Sponsor